Last reviewed · How we verify
GB224 30mg — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
GB224 30mg (GB224 30mg) — Genor Biopharma Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GB224 30mg TARGET | GB224 30mg | Genor Biopharma Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GB224 30mg CI watch — RSS
- GB224 30mg CI watch — Atom
- GB224 30mg CI watch — JSON
- GB224 30mg alone — RSS
Cite this brief
Drug Landscape (2026). GB224 30mg — Competitive Intelligence Brief. https://druglandscape.com/ci/gb224-30mg. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing